Poster Presentation Australasia Extracellular Vesicles Conference 2017

Transcriptome and long noncoding RNA sequencing of three extracellular vesicle subtypes released from the human colon cancer LIM1863 cell line (#43)

Maoshan Chen 1 , Rong Xu 1 , Hong Ji 1 , David Greening 1 , Alin Rai 1 , Wittaya Suwakulsiri 1 , Keiichi Izumikawa 2 3 , Hideaki Ishikawa 2 3 , Nobuhiro Takahashi 2 3 , Richard Simpson 1 3
  1. La Trobe Institute for Molecular Science, Melbourne, VIC, Australia
  2. Department of Applied Biological Science, Tokyo University of Agriculture and Technology, Tokyo, Japan
  3. Global Innovation Research Organisation, Tokyo University of Agriculture and Technology, Tokyo, Japan

Previously we reported that LIM1863 colorectal cancer (CRC) cells secrete three distinct extracellular vesicle subtypes – two subpopulations of exosomes (apical EpCAM-Exos and basolateral A33-Exos) and shed microvesicles (sMVs) – with distinct protein and miRNA signatures. Here, we extend our omics approach to understand the fundamental role of LIM1863-derived EVs by performing a comprehensive analysis of their mRNAs and long non-coding RNAs (lncRNAs) using RNA-Seq. We show that 2,389 mRNAs, 317 pseudogene transcripts, 1,028 lncRNAs and 206 short non-coding RNAs selectively distributed to (i.e., are enriched in) LIM1863 EVs, relative to the parent cell. An Ensembl/UniProtKB analysis revealed 1,937 mRNAs encode canonical proteins, 348 isoforms (including splice-variant proteins), and 119 ‘missing proteins’ (i.e., annotated in Ensembl but not UniProtKB). Further dissection of our protein/RNA data revealed that 6/151 observed RNA binding proteins have the potential to interact with ~75% of EV-enriched RNAs. Intriguingly, the co-existence of U1 and U2 ribonucleoproteins and their cognate snRNAs in LIM1863 EVs suggests a possible association of CRC EVs with recipient cell splicing events. Our data reveal several potential lncRNA CRC biomarkers and novel splicing/fusion genes that, collectively, will advance our understanding of EV biology in CRC and accelerate the development of EV-based diagnostics and therapeutics.